RegMed Investors’ (RMi) pre-open: Wait for it, wait for it

March 11, 2025 7:48am

It’s coming, what – a BUY opportunity, not totally today, maybe tomorrow; we will be ready for the most down sector equities  

Econs will manage any swings during this week; if or once you see/perceive the green(s) on the sector screen – fire with your buy tickets

Pre-open Indication: 3 Positive and 3 Negative Indications

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief …

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

Friday’s night’s … RegMed Investors (RMi) Closing Bell: a dine and dash week ending … https://www.regmedinvestors.com/articles/13831

Beam Therapeutics (BEAM) an offering of 16,151,686 shares priced at $28.48 per share … https://www.regmedinvestors.com/articles/13832

Tuesday; The pre-open Dow futures are UP +0.37% or (+155 points), the S&P futures are UP +0.48% or (+26 points) and the Nasdaq futures are UP +0.58% or (+110 points)

• Stock futures edged higher Tuesday, 3/11
• European markets opened lower,
• Asia-Pacific markets slid down

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Indexes and equities sank during Monday’s session, extending losses after the S&P 500 posted 3 consecutive negative weeks, the Nasdaq also saw its worst day since September 2022 while, the Dow lost nearly 900 points, closed below its 200-day moving average for the first time since Nov. 1, 2023.

• Monday: The Dow closed DOWN -890.01 points or -2.08%, the S&P closed DOWN -155.63 points or -2.69% while the Nasdaq closed DOWN -727.90 points or -4%

Economic Data Docket: Job openings data

• Followed by February’s reading of the consumer price index on Wednesday morning and that month’s data for the producer price index on Thursday.

Q1/25:  March sessions with 1 positive and 5 negative closes

• February – 1 holiday, 11 negative and 8 positive closes
• January – 2 holidays, 1 market close, 10 negative and 10 positive closes

Q4/24:

• December 1 holiday, 15 negative and 5 positive closes
• November 10 negative and 9 positive closes
• October: 8 positive and 15 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty.

Although, pre-open bottom feeding ...

Positive Indication:

• Alnylam Pharmaceuticals (ALNY) closed down -$11.45 with a positive +0.43 or +0.18%
• Beam Therapeutics (BEAM) closed down -$2.79 with a positive +0.84 or +3.27%
• CRISPR Therapeutics (CRSP) closed down -$2.19 with a positive +0.27 or +0.62%

Although, Negative Indication:

• Ionis Pharmaceuticals (IONS) closed down -$11.59 with a negative -$0.22 or -0.68%
• UniQure NV (QURE) closed down -$0.53 with a negative -$0.20 or -1.71%
• Sage therapeutics (SAGE) closed down -$0.23 with a negative -$0.07 or -0.96%

The BOTTOM LINE: the new month, March's 2nd week continues … NOT much has changed – diving market, as I have written, “uncle algo and his trading dwarfs” will determine the heights or lows of share pricing”

March to date: 1 Positive and 5 Negative closes

• 3/10 – Monday closed negative with 3 positive, 31 negative and 1 flat
• 3/8 – Friday closed negative with 14 positive, 17 negative and 4 flats
• 3/6 – Thursday closed negative with 16 positive, 18 negative and 1 flat
• 3/5 – Wednesday closed positive with 25 positive, 9 negative and 1 flat
• 3 /4 – Tuesday closed negative with 15 positive, 18 negative and 2 flats
• 3/3 – Monday closed negative with 2 positive, 31 negative and 2 flats

Reiterating, “I think it's important just to take a step back, focus on the fundamentals, be selective. I mean, this has definitely been a “sucky” January and February from a stock-picker standpoint given the up/downs. And so, I am relatively neutral across today/Friday’s equity strategy.

• Reiterating, “Take the emotion out of the sector, think of the reality of the “plays” that exist of who’s really buying.”

It’s STILL earnings season “sparking” a quarterly life crisis…

• Cell and Gene therapy earnings continue to be important; LPS (loss per share), revenue uplifts and lags, clinical progress with some program uncertainty, a dearth all followed by estimate misses
• The coming batch of quarterly earnings will provide last years, FY2024’s LPS (loss-per-share), some EPS, consensus meets and non-greets, cash positions, runways and partner status for investors

Earnings are here … from Q4/24 and FY24 … my view will follow, has been busy and personally eventful!

• Caribou Biosciences (CRBU – Monday, 3/10
• Agenus (AGEN) – Tuesday, 3/11
• Voyager Therapeutics (VYGR) - Tuesday, 3/11
• Cellectis SA (CLLS) – Thursday, 3/13
• Sangamo Therapeutics (SGMO), Monday, 3/17

Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject.

Welcome to my world of defining the “grey’ in our universe!

• The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.